Ipsen news:Corporate News
Corporate News
Keyhighlights·IpsencompletesacquisitionofAlbireo,expandingthescopeofitsRareDiseaseportfolio·IpsentopresentnewBylvay®(odevixibat)dataat ...。其他文章還包含有:「Pressreleases」、「Ipsen–improvingpatienthealthoutcomes」、「PressReleases」、「Ipsendeliverssolidsalesgrowthinthefirstninemonthsof...」、「MediaLibrary」、「IpsenS.A.(IPN.PA)StockPrice」、「Ipsenisofficiallyrecognizedasagreatplacetowor...
查看更多 離開網站Press releases
https://www.ipsen.com
A comprehensive library of Ipsen media releases for investors and members of the press. Press Releases · Media Statements · Media Library. Key highlights.
Ipsen – improving patient health outcomes
https://www.ipsen.com
Ipsen is a global biopharmaceutical company, improving patients' lives through research and innovation in oncology, rare disease & neuroscience.
Press Releases
https://www.ipsen.com
Dublin, Ireland, 25th/26th September 2022 Tánaiste joins Ipsen Ireland to launch upgraded manufacturing site in… See more · Ipsen announced overall Pharma ...
Ipsen delivers solid sales growth in the first nine months of ...
https://www.ipsen.com
Based on the solid sales momentum, today we are confirming our guidance for the full year. Further good news from the pipeline, including the ...
Media Library
https://www.ipsen.com
A comprehensive library of Ipsen media content, including photo and video materials, for members of the press.
Ipsen S.A. (IPN.PA) Stock Price
https://finance.yahoo.com
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance. Paris (France), 26 October 2023 Ipsen (Euronext: IPN ...
Ipsen is officially recognized as a great place to work ...
https://www.ipsen.com
In October, Ipsen was officially recognized by the Great Place to Work group in 14 countries: Algeria, Brazil, Canada, Colombia, Greece, Ireland ...
Ipsen Biopharmaceuticals
https://www.ipsen.com
Ipsen is a mid-sized global biopharmaceutical company, improving patients' lives through research and innovation in oncology, rare disease and neuroscience.